1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1385/endo:21:1:67" target="_blank" rel="noreferrer noopener">http://doi.org/10.1385/endo:21:1:67</a>
Pages
67–75
Issue
1
Volume
21
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.
Publisher
An entity responsible for making the resource available
Endocrine
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
2003-06
Subject
The topic of the resource
Humans; Sex Characteristics; Estrogens/*pharmacology; *Neuroprotective Agents; Basal Ganglia Diseases/prevention & control; Dopamine/*physiology; Neostriatum/cytology/drug effects/*physiology; Parkinson Disease/pathology/prevention & control; Substantia Nigra/cytology/drug effects/*physiology
Creator
An entity primarily responsible for making the resource
Dluzen Dean; Horstink Martin
Description
An account of the resource
In this review, we relate both laboratory and clinical evidence associated with the capacity for estrogen to function as a modulator of nigrostriatal dopaminergic pathology. To accomplish this goal, we have divided this review into three parts. In Part 1, we provide a brief historical perspective of studies that have laid the groundwork for demonstrating the existence of hormonal- nigrostriatal interactions. In Part 2, we focus specifically on laboratory data that show the ability and conditions by which estrogen may function as a neuroprotectant of the nigrostriatal dopaminergic system. Finally, in Part 3, we review the clinical literature related to this issue as a means for consideration of estrogen as a modulator, neuroprotectant, and therapy for Parkinson disease.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1385/endo:21:1:67" target="_blank" rel="noreferrer noopener">10.1385/endo:21:1:67</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Neuroprotective Agents
2003
Basal Ganglia Diseases/prevention & control
Dluzen Dean
Dopamine/*physiology
Endocrine
Estrogens/*pharmacology
Horstink Martin
Humans
Neostriatum/cytology/drug effects/*physiology
Parkinson Disease/pathology/prevention & control
Sex Characteristics
Substantia Nigra/cytology/drug effects/*physiology